Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma

BACKGROUND: We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable biliary tract carcinoma (BTC). METHODS: A total of 28 patients (27 were evaluable) with advanced BTCs who progressed o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tella, Sri Harsha, Foster, Nathan, Qian, Shi, Nguyen, Tran, Borad, Mitesh J, McWilliams, Robert R, Alberts, Steven R, Wee Ma, Wen, Chakrabarti, Sakti, Fruth, Briant, Wessling, Jaclynn, Hartgers, Mindy, Washburn, Leslie, Fernandez-Zapico, Martin E, Hogenson, Tara L, Pitot, Henry, Jin, Zhaohui, Mahipal, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546810/
https://www.ncbi.nlm.nih.gov/pubmed/37339254
http://dx.doi.org/10.1093/oncolo/oyad144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546810/
https://www.ncbi.nlm.nih.gov/pubmed/37339254
http://dx.doi.org/10.1093/oncolo/oyad144

Ejemplares similares